| ID: | 176 | |
|---|---|---|
| Name: | Compound 176 | |
| Description: | Original numeration in publication: 16 | |
| Labels: | Test_set, Thiazolidine-2, 4-dione | |
| CAS: | ||
| InChi Code: | InChI=1S/C26H19Cl2N3O4S/c27-19-9-6-18(21(28)13-19)12-22-25(34)31(26(35)36-22)15-23(32)30-20-10-7-17(8-11-20)24(33)29-14-16-4-2-1-3-5-16/h1-13H,14-15H2,(H,29,33)(H,30,32)/b22-12- |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.74 |
El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. A., R. R.; Mahdy, H. A.; Nasser, M. a. A., H. S.; El-Hddad, S. S. A. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000279. https://doi.org/10.1002/ardp.202000279 |
| 6.30301 |
Eq1: VEGFR-2 inhibition (Data used to validate model) |